This is a human monochlonal antibody that is not likely to cause allergic reactions or tolerance as would Infliximab and is used as sub-cutaneous injection once every 2 weeks at a dose of 20-40mg. It can be uncomfortable and it is as effective as the 8 weekly infusions of Infliximab are. Both Infliximab and Adalimumab can be used for ulcerative colitis and Crohn’s disease but NICE guidance is present only for Crohn’s disease in children.

Sign up to our newsletter